Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer

Basit Öğe Kaydı
dc.authoridAyhan, Sevgi/0000-0003-1697-8583|Gungor, Tayfun/0000-0002-7869-9662
dc.contributor.authorBeyazit, Fatma
dc.contributor.authorAyhan, Sevgi
dc.contributor.authorCelik, Huseyin Tugrul
dc.contributor.authorGungor, Tayfun
dc.date.accessioned2025-10-24T18:08:48Z
dc.date.available2025-10-24T18:08:48Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractClinicopathologic and molecular studies have provided new insights and understanding on the pathological events during ovarian carcinogenesis. Moreover, angiotensin II-enhanced tumor cell invasion via type 1 angiotensin II receptor in ovarian cancer cell lines was recently demonstrated. It has been suggested that renin-angiotensin system (RAS) activity increases in diseases involving the female reproductive system. In the present study, we aimed to analyze the possible relationship between the levels of circulating angiotensin-converting enzyme (ACE), an important molecule of RAS, and ovarian cancer (OC). This study was conducted in 41 epithelial OC patients (mean age 56.1 +/- A 10.2 years) and 19 healthy controls (mean age 53.4 +/- A 13.1 years). Clinical and laboratory features are summarized. Serum ACE and Ca-125 levels were measured using commercially available laboratory kits. Serum ACE levels of epithelial OC patients and controls were 30.58 +/- A 13.37 and 14.15 +/- A 3.67, respectively. Serum ACE levels were significantly elevated in epithelial OC patients in comparison to healthy controls. Ca-125 levels of epithelial OC patients were also significantly elevated in epithelial OC patients. No correlation was observed between ACE levels and Ca-125 levels. In epithelial OC patients, serum ACE levels did not differ according to stages and pathologic subtypes of the patients. Our results showed that serum ACE levels were increased in OC patients. Being an important component of RAS, circulating ACE might be associated with ongoing pathobiologic events in ovarian carcinogenesis. Therefore, targeting the RAS pathway could provide a future treatment strategy for this cancer type.
dc.identifier.doi10.1007/s00404-015-3661-x
dc.identifier.endpage420
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue2
dc.identifier.pmid25693759
dc.identifier.scopus2-s2.0-84930540114
dc.identifier.scopusqualityQ2
dc.identifier.startpage415
dc.identifier.urihttps://doi.org/10.1007/s00404-015-3661-x
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3309
dc.identifier.volume292
dc.identifier.wosWOS:000355864000028
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofArchives Of Gynecology And Obstetrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectEpithelial ovarian carcinoma; Angiotensin-converting enzyme; Renin-angiotensin system; Ca-125
dc.titleAssessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu